Editorial: TNFRSF agonists: mode of action and therapeutic opportunities.

Obermajer, Natasa; Zwolak, Adam; Wajant, Harald

Obermajer, Natasa; Zwolak, Adam; Wajant, Harald.

Afiliación

Obermajer N; Oncology R&D, Johnson and Johnson Innovative Medicine, Beerse, Belgium.
Zwolak A; Therapeutics Discovery, Johnson and Johnson Innovative Medicine, Spring House, PA, United States.
Wajant H; Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.

Front Immunol ; 14: 1328100, 2023.

Article en En | MEDLINE | ID: mdl-38022660

Asunto(s)

Receptores del Factor de Necrosis Tumoral; Receptores del Factor de Necrosis Tumoral/agonistas

Palabras clave

Fcgamma receptor; TNFRSF; agonism; antibody design; co-stimulation; immunostimulation; immunotherapy; signaling/signaling pathways

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores del Factor de Necrosis Tumoral Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google